Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSTO1 | P78417 | 2/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.59 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.46 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4779257 | 0.88 | ALOX5 (0.51) | GSTO1PTPN1ALOX5PSEN1NR1I2 | |
| SCHEMBL5445014 | 0.85 | ALOX5 (0.63) | ALOX5MEN1KMT2ANR1I2 | |
| SCHEMBL3096678 | 0.82 | MEN1 (0.65) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL13156985 | 0.82 | MEN1 (0.65) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL17991478 | 0.82 | GSTO1 (0.70) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL5806822 | 0.78 | ALOX5 (0.57) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL3112441 | 0.78 | GSTO1 (0.93) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL20822167 | 0.78 | PTPN1 (0.45) | GSTO1PTPN1ALOX5PSEN1NR1I2 | |
| SCHEMBL17164637 | 0.76 | GSTO1 (0.52) | GSTO1PTPN1ALOX5MEN1KMT2A | |
| SCHEMBL7799047 | 0.76 | PSEN1 (0.45) | GSTO1PTPN1ALOX5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | WECHTER WILLIAM J | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037878-A1 | Use of gamma-tocopherol and its oxidative metabolite LLU-alpha in the treatment of disease | TTPA, LTA, GSTM1 | GSTO1 6/4885PTPN1 2288/4885ALOX5 150/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.